Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II of Zoledronic Acid (Zometa) in the Prevention of Osteoporosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00321932 is registered in ClinicalTrials.gov with University of Minnesota as lead sponsor.

NCT NCT00321932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00321932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II of Zoledronic Acid (Zometa) in the Prevention of Osteoporosis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
University of Minnesota
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
March 31, 2012
Enrollment
61 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma, myelodysplastic syndromes, osteoporosis, ovarian cancer